What is Ada Health's primary value proposition?

Ada Health positions itself as a 'gold standard' symptom assessment tool that bridges the gap between personal health management and professional care. According to slide 3, its value proposition centers on 24/7 access to medical-grade assessments, personalized care navigation, and providing population-level data insights to health systems and partners.

How does Ada Health compare to its competitors clinically?

The deck places clinical superiority at the forefront. Slide 7 shows that Ada achieves 71% accuracy for top-three condition suggestions, which is double the 38% average of its competitors. Additionally, slide 7 claims 99% condition coverage and 97% advice safety, which the company states is on par with human doctors.

Who are Ada Health's key partners?

Ada demonstrates significant B2B traction by listing several 'Digital Health Champions' as partners. Slide 8 highlights logos from diverse sectors, including pharmaceutical giants like Pfizer and Takeda, technology leaders like Samsung, and healthcare providers such as Sutter Health and the NHS.

What evidence of user traction does the deck provide?

The deck provides substantial social proof. Slide 3 notes 10 million users and 20 million assessments. Slide 5 adds that one user turns to Ada for guidance every three seconds. Slide 9 showcases a 4.7-star rating from over 270,000 reviews, alongside testimonials from both patients and medical experts.

What is missing from this pitch deck?

This is a high-level 'vision and traction' deck. It lacks a 'Problem' slide (assuming the problem is understood), a 'Market Size' (TAM/SAM/SOM) slide, a detailed 'Business Model' explanation, and any 'Financials.' Most importantly, there is no 'The Ask' slide detailing how much capital is being raised or how it will be spent.

Ada Health Pitch Deck: Slide-by-Slide Breakdown

Ada Health’s 11-slide Series B pitch deck, dated May 2021, is a masterclass in establishing clinical authority. Rather than leading with revenue or market size, the company focuses on its nine years of R&D and a user base of over 10 million people. The deck leans heavily on third-party validation, citing studies that place its diagnostic accuracy at 71%—significantly higher than the 38% competitor average. While the deck excels at proving product-market fit and clinical safety, it is notably silent on business model specifics, revenue figures, and the specific 'ask' for the round. It function…

Key takeaways

The company claims over 10 million users and 20 million assessments completed as of May 2021 (Slide 3).
Ada asserts a diagnostic accuracy of 71%, which it compares to a competitor average of 38% (Slide 3).
The platform covers 99% of conditions, the highest among its competitive set (Slide 7).
A case study with the NHS suggests 15% of patients would have avoided a clinic visit if they had used Ada first (Slide 6).
The team is highly experienced, with the four featured executives totaling over 85 years of combined experience (Slide 10).
The deck lists major global partners including Pfizer, Samsung, Takeda, and Sutter Health (Slide 8).
User engagement is high, with a 4.7/5.0 rating across 270,000+ in-app reviews (Slide 9).
The deck contains no financial projections, revenue data, or specific funding requirements (Slides 1-11).

Introduction and Brand Identity

Slides 1-2: The Vision

The deck opens with a minimalist title slide (Slide 1) dated May 2021, establishing a clean, professional aesthetic consistent with a medical technology firm. Slide 2 defines the company's purpose: "To improve human health by transforming knowledge into better outcomes." This sets a high-level tone, focusing on the result of the technology rather than the technology itself.

The Executive Summary

Slide 3: Ada at a Glance

Slide 3 is the most data-dense slide in the deck, serving as a comprehensive executive summary. It breaks down the company into four quadrants: traction, value proposition, clinical AI partnerships, and competitive benchmarking. Key figures include +10M users , +20M assessments , and +9 years of R&D . The company also notes it employs 230 people, including ~50 medical experts. This slide introduces the core competitive claim: a 71% diagnostic accuracy compared to a 38% competitor average, and 97% advice safety , which it claims is on par with GPs.

Product and Differentiation

Slide 4: The User Journey

Slide 4 visualizes the product experience through a six-step mobile interface sequence. It categorizes the journey into three phases: Diagnostic Information (Health guide, conversational interface, diagnostic reasoning), Access (Direct access to HC professional), and Management (Symptom tracking and personal health profile). This illustrates that Ada is not just a chatbot, but a full-cycle health management platform.

Slide 5: The Moat

Slide 5 focuses on the pillars of Ada's differentiation. It highlights Clinical leadership (validated by external studies), User trust (one user every three seconds), Scalability (provider-agnostic digital platform), and Rich data insights derived from the 20 million completed assessments. This slide aims to convince investors that the company has a defensible lead built on data and clinical rigor.

Clinical Validation and Competition

Slide 6: The NHS Case Study

To prove real-world utility, Slide 6 presents data from a large NHS GP clinic involving 500 patients and 20 doctors. The results are compelling: 97% found the app easy to use, and 15% of patients would have opted for self-care or a pharmacy instead of visiting the clinic if they had used Ada first. This directly addresses the "redirection of care" value proposition for overstrained health systems.

Slide 7: Competitive Benchmarking

Slide 7 doubles down on the clinical data introduced in Slide 3. It uses three bar charts to show Ada leading in condition coverage (99%) , accuracy (71%) , and advice safety (97%) . By placing itself next to a sea of unnamed "Competition" bars, Ada positions itself as the only viable medical-grade solution in a crowded market of lower-quality apps.

Partnerships and Social Proof

Slide 8: The Partner Ecosystem

Slide 8 is a logo wall featuring "Medical & Digital Health Champions." The inclusion of Sutter Health, Takeda, Pfizer, Samsung, and Labor Berlin suggests that Ada has successfully navigated the complex procurement cycles of global enterprises. This serves as a proxy for a business model slide, implying revenue through B2B licensing and integration.

Slide 9: User and Expert Endorsements

Slide 9 provides qualitative proof to match the quantitative data. It features four consumer testimonials—including one claiming the app "saved my life"—and endorsements from a US telemedicine company's clinical team and GP feedback. The slide reinforces the 4.7/5.0 rating from 270,000+ ratings , emphasizing that the product is beloved by the end-user, not just the enterprise buyer.

Team and Conclusion

Slide 10: The Management Team

The team slide features four leaders: Daniel Nathrath (CEO, +20 years experience), Dr. Martin Hirsch (CSO, +25 years), Dr. Claire Novorol (CMO, +15 years), and Urban Liebel (CTO, +25 years). The logos beneath their names (BCG, NHS, KIT) and their advanced degrees (PhD, MD) underscore the "founder-led" and "expert-driven" nature of the business. The combined experience exceeds 85 years, which is significant for a Series B stage company.

Slide 11: Closing

The deck ends abruptly with a "Thank you" slide. There is no summary of the investment opportunity or contact information on this final page.

What Works

Clinical Credibility: The deck repeatedly cites third-party validation and comparative studies. In healthcare, safety and accuracy are the primary hurdles, and Ada addresses them head-on. · Traction at Scale: 10 million users and 20 million assessments are massive numbers that prove the product is not a pilot or a prototype. · B2B Validation: The partner slide (Slide 8) shows that the world's largest healthcare and tech companies trust Ada's engine. · Visual Clarity: The deck uses a consistent, high-end design that feels "medical" yet modern.

What is Missing

The Ask: There is no mention of how much money is being raised, the valuation, or the use of proceeds. · Financials: There are zero mentions of revenue, ARR, burn rate, or even the basic business model (SaaS vs. per-assessment vs. licensing). · Market Size: The deck assumes the investor already knows the digital health market is huge. It lacks a TAM/SAM/SOM slide. · Roadmap: There is no "Future" slide. Investors want to know what the next 18-24 months look like, but this deck focuses entirely on what has already been achieved.

What a Founder Should Copy

The "At a Glance" Slide: Slide 3 is an excellent template for an executive summary. It combines traction, value prop, and social proof in one view. · Benchmarking: If you have data showing you are 2x better than the competition (as seen on Slide 7), use bar charts to make that gap visual and undeniable. · Case Studies: The NHS slide (Slide 6) is a perfect example of how to use a single pilot to prove a massive economic benefit (reducing clinic visits). · Expertise-First Team Slide: Highlighting the specific years of experience and professional designations (MD, PhD) is crucial for deep-tech or healthcare startups.

Frequently asked questions

What is Ada Health's primary value proposition?: Ada Health positions itself as a 'gold standard' symptom assessment tool that bridges the gap between personal health management and professional care. According to slide 3, its value proposition centers on 24/7 access to medical-grade assessments, personalized care navigation, and providing population-level data insights to health systems and partners.
How does Ada Health compare to its competitors clinically?: The deck places clinical superiority at the forefront. Slide 7 shows that Ada achieves 71% accuracy for top-three condition suggestions, which is double the 38% average of its competitors. Additionally, slide 7 claims 99% condition coverage and 97% advice safety, which the company states is on par with human doctors.
Who are Ada Health's key partners?: Ada demonstrates significant B2B traction by listing several 'Digital Health Champions' as partners. Slide 8 highlights logos from diverse sectors, including pharmaceutical giants like Pfizer and Takeda, technology leaders like Samsung, and healthcare providers such as Sutter Health and the NHS.
What evidence of user traction does the deck provide?: The deck provides substantial social proof. Slide 3 notes 10 million users and 20 million assessments. Slide 5 adds that one user turns to Ada for guidance every three seconds. Slide 9 showcases a 4.7-star rating from over 270,000 reviews, alongside testimonials from both patients and medical experts.
What is missing from this pitch deck?: This is a high-level 'vision and traction' deck. It lacks a 'Problem' slide (assuming the problem is understood), a 'Market Size' (TAM/SAM/SOM) slide, a detailed 'Business Model' explanation, and any 'Financials.' Most importantly, there is no 'The Ask' slide detailing how much capital is being raised or how it will be spent.